at a dose of 200 \g=m\g was given daily for 2 months to 6 women with polycystic ovarian disease (PCO). Prior to therapy the patients presented elevated LH, testosterone (T), oestrone (E1) and dihydrotestosterone (DHT) in the circulation. In response to GnRH-A, these subjects exhibited a marked decrease in circulating T, DHT and androstenedione (A) levels as measured 24 h after GnRH-A injection, by 4 weeks and onwards (P < 0.05). After 2 weeks of daily administration, the serum LH profile, evaluated by sampling at 2, 4. 7 and 24 h after injection of GnRH-A, was not different from baseline, whereas after 4, 6 and 8 weeks the levels were significantly lower (*P < 0.01). The profile of serum T levels was unmodified at the second week, but significantly decreased thereafter (*P <0.01). At the end of treatment, the E1 concentrations, elevated in pre-injection condition, were markedly decreased. These data demonstrate that in PCO subjects, GnRH-A significantly lowered the elevated levels of androgens commonly found in these patients. 
jects exhibited a marked decrease in circulating T, DHT and androstenedione (A) levels as measured 24 h after GnRH-A injection, by 4 weeks and onwards (P < 0.05). After 2 weeks of daily administration, the serum LH profile, evaluated by sampling at 2, 4. 7 and 24 h after injection of GnRH-A, was not different from baseline, whereas after 4, 6 and 8 weeks the levels were significantly lower (*P < 0.01). The profile of serum T levels was unmodified at the second week, but significantly decreased thereafter (*P <0.01). At the end of treatment, the E1 concentrations, elevated in pre-injection condition, were markedly decreased. These data demonstrate that in PCO subjects, GnRH-A significantly lowered the elevated levels of androgens commonly found in these patients. The close correlation observed between reduced serum LH and androgen concentrations suggests that pituitary desensitization could be responsible for the reduction in androgen levels, and may be evidence for a gonadotrophin de- pendence of the elevated concentrations of T in these patients.
Hormonal findings in polycystic ovarian disease (PCO) are well established. These include elevated LH levels with an increased serum LH/FSH ratio, and elevated serum androgens (DeVane et al. 1975; . Numerous investiga¬ tors have shown increased concentrations of (DeVane et al. 1975 ; Greenblatt & Mahesh 1976) in the peripheral circulation.
The specific glandular source (adrenal or ovar¬ ian T) of the excess androgen production in PCO is controversial, although hvperandrogenism in polvcvstic ovarain disease seems to be partially LH-dependent, since there is a direct temporal correlation between the suppression of LH by oral contraceptive and the decrease in plasma levels of A and (Givens et al. 1974 ). The elevated LH levels, then, might stimulate ovarian androgen production by direct stimulation of the ovarian theca cells (Erickson et al. 1979) , regardless of whether the initial source of excess androgens is adrenal or ovarian.
It has been widely reported that appropriate administration of gonadotrophin-releasing hor¬ mone agonists (GnRH-A) paradoxically, 'down- regulates' the pituitary, resulting in a decrease in gonadotrophins and gonadal steroids (Bergquist et al. 1979a ,b: Clayton 1982 . Consequently, chro¬ nic administration of these analogues has been used in humans for treating diseases in which a lowering of gonadal steroids may be of value (Comité et al. 1981 ; Koutsilieris & Tolis 1983 (Fig. 2) .
The serum levels during a 24-h period in analogue-treated subjects are depicted in Fig. 3 . Serum concentrations were substantially un¬ modified at the second week, thereafter the responses to GnRH-A were characterized by a steady decline, in fact, at all points for each week, when considered together, were found to be sig¬ nificantly different from the 24-h baseline profile (*P < 0.01). In each subject the maximal inhibi¬ tion of levels occurred in those samples col¬ lected 24 h after daily injection. It is noteworthy that, during month 2 of treatment, the serum concentrations of remained within the normal range throughout the day.
Clinical and laboratory data for each subject at the end of treatment are shown in (Faure et al. 1982; Tolis et al. 1983 ). This indicates that one single blood sample collected 24 h after injection may not necessarily reflect the hormonal changes provoked by the analogue.
LH is known as a potential regulator of ovarian androgen production by a direct stimulation of the ovarian theca cells (Erickson et al. 1979) , and GnRH-A administration seems to inhibit the ova¬ rian androgen selectively, but does not affect the adrenal source of these hormones in PCO (Chang et al. 1983 (Meldrum et al. 1984) . These 
